Share ownership GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:28 2025-06-20 am EDT			5-day change	1st Jan Change
1,402.50 ^GBX	-2.26%		-7.21%	+4.16%

Jun. 20	UK's FTSE 100 sees first weekly fall in six; Middle East tensions in focus	RE
Jun. 20	FTSE 100 underperforms Europe despite Iran talks	AN

Share class: GSK plc

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	4,315,116,636	4,078,489,304 ( 94.52 %)	169,171,155 ( 3.92 %)	94.52 %

Major shareholders: GSK plc

Name	Equities	%	Valuation
The Vanguard Group, Inc. 3.517 %	145,425,950	3.517 %	2 955 M p
BlackRock Fund Advisors 3.077 %	127,225,000	3.077 %	2 586 M p
Dodge & Cox 2.404 %	99,377,874	2.404 %	2 020 M p
Schroder Investment Management Ltd. 1.898 %	78,489,655	1.898 %	1 595 M p
Wellington Management Co. LLP 1.772 %	73,272,893	1.772 %	1 489 M p
Norges Bank Investment Management 1.7 %	70,298,000	1.7 %	1 429 M p
BlackRock Advisors (UK) Ltd. 1.656 %	68,458,684	1.656 %	1 391 M p
Legal & General Investment Management Ltd. 1.44 %	59,526,533	1.44 %	1 210 M p
Silchester International Investors LLP 1.188 %	49,126,000	1.188 %	998 M p
SSgA Funds Management, Inc. 1.18 %	48,790,684	1.18 %	992 M p
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Dodge & Cox 3.805 %	78,651,833	3.805 %	3 227 M p
Fidelity Management & Research Co. LLC 2.908 %	60,120,517	2.908 %	2 467 M p
Fisher Asset Management LLC 1.453 %	30,031,815	1.453 %	1 232 M p
PRIMECAP Management Co. 1.244 %	25,708,020	1.244 %	1 055 M p
JTC Employer Solutions Trustee Ltd. 0.7382 %	15,260,368	0.7382 %	626 M p
RBC Private Counsel (USA), Inc. 0.4701 %	9,717,417	0.4701 %	399 M p
Goldman Sachs Wealth Services LP 0.4384 %	9,062,887	0.4384 %	372 M p
UBS Financial Services, Inc. 0.3769 %	7,790,988	0.3769 %	320 M p
T. Rowe Price International Ltd. 0.3736 %	7,722,314	0.3736 %	317 M p
State Street Corp. 0.3373 %	6,972,998	0.3373 %	286 M p
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	54.79%
Other	2.95%
Individuals	0.34%
Governments	0.03%
Credito Emiliano SpA	0.01%
Unknown	41.88%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	23.06%
United Kingdom	21.4%
Switzerland	2.01%
Norway	1.88%
Germany	1.69%
Canada	0.83%
France	0.83%
Italy	0.73%
Japan	0.63%
Netherlands	0.55%
Sweden	0.54%
Australia	0.51%
Spain	0.44%
Singapore	0.39%
Ireland	0.38%
Individuals	0.34%
Luxembourg	0.32%
South Korea	0.31%
Denmark	0.3%
Hong Kong	0.25%
Belgium	0.24%
Finland	0.15%
South Africa	0.11%
Austria	0.11%
Kazakhstan	0.03%
Bahamas	0.02%
New Zealand	0.02%
Portugal	0.01%
Thailand	0.01%
Taiwan	0.01%

Based on 1000 largest holdings

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Employees

68,629

Sector

Pharmaceuticals

Calendar

Jul. 30 - Q2 2025 Earnings Release

More about the company